• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病前驱期和早期的影像学生物标志物。

Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease.

机构信息

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Multimodal Neuroimaging Group, Cologne, Germany.

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.

出版信息

J Parkinsons Dis. 2024;14(s2):S353-S365. doi: 10.3233/JPD-230385.

DOI:10.3233/JPD-230385
PMID:38339941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11492013/
Abstract

Assessing imaging biomarker in the prodromal and early phases of Parkinson's disease (PD) is of great importance to ensure an early and safe diagnosis. In the last decades, imaging modalities advanced and are now able to assess many different aspects of neurodegeneration in PD. MRI sequences can measure iron content or neuromelanin. Apart from SPECT imaging with Ioflupane, more specific PET tracers to assess degeneration of the dopaminergic system are available. Furthermore, metabolic PET patterns can be used to anticipate a phenoconversion from prodromal PD to manifest PD. In this regard, it is worth mentioning that PET imaging of inflammation will gain significance. Molecular imaging of neurotransmitters like serotonin, noradrenaline and acetylcholine shed more light on non-motor symptoms. Outside of the brain, molecular imaging of the heart and gut is used to measure PD-related degeneration of the autonomous nervous system. Moreover, optical coherence tomography can noninvasively detect degeneration of retinal fibers as a potential biomarker in PD. In this review, we describe these state-of-the-art imaging modalities in early and prodromal PD and point out in how far these techniques can and will be used in the future to pave the way towards a biomarker-based staging of PD.

摘要

评估帕金森病(PD)前驱期和早期的影像学生物标志物对于确保早期和安全诊断非常重要。在过去的几十年中,成像方式不断发展,现在能够评估 PD 中许多不同的神经退行性变方面。MRI 序列可以测量铁含量或神经黑色素。除了 Ioflupane 的 SPECT 成像外,还有更具体的 PET 示踪剂可用于评估多巴胺能系统的退化。此外,代谢 PET 模式可用于预测前驱期 PD 向显性病 PD 的表型转化。在这方面,值得一提的是,炎症的 PET 成像将变得重要。神经递质如 5-羟色胺、去甲肾上腺素和乙酰胆碱的分子成像为非运动症状提供了更多信息。在大脑之外,心脏和肠道的分子成像用于测量与 PD 相关的自主神经系统退化。此外,光学相干断层扫描可以无创地检测视网膜纤维的退化,作为 PD 的潜在生物标志物。在这篇综述中,我们描述了早期和前驱 PD 中的这些最先进的成像方式,并指出这些技术在未来可以在多大程度上用于为 PD 的基于生物标志物的分期铺平道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed44/11492013/2b4c325bd4ca/jpd-14-jpd230385-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed44/11492013/2b4c325bd4ca/jpd-14-jpd230385-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed44/11492013/2b4c325bd4ca/jpd-14-jpd230385-g001.jpg

相似文献

1
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease.帕金森病前驱期和早期的影像学生物标志物。
J Parkinsons Dis. 2024;14(s2):S353-S365. doi: 10.3233/JPD-230385.
2
Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.临床前期和前驱期帕金森病的电路成像生物标志物。
Mol Med. 2021 Sep 16;27(1):111. doi: 10.1186/s10020-021-00327-x.
3
Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review.帕金森病各疾病阶段新兴神经影像学生物标志物的研究进展:综述
JAMA Neurol. 2021 Oct 1;78(10):1262-1272. doi: 10.1001/jamaneurol.2021.1312.
4
The role of neuroimaging in Parkinson's disease.神经影像学在帕金森病中的作用。
J Neurochem. 2021 Nov;159(4):660-689. doi: 10.1111/jnc.15516. Epub 2021 Oct 3.
5
Four-Year Follow-up of [ F]Fluorodeoxyglucose Positron Emission Tomography-Based Parkinson's Disease-Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression.20 例孤立性快速眼动睡眠行为障碍患者基于[ F]氟脱氧葡萄糖正电子发射断层扫描的帕金森病相关模式表达的四年随访显示前驱进展。
Mov Disord. 2021 Jan;36(1):230-235. doi: 10.1002/mds.28260. Epub 2020 Sep 10.
6
The Concept of Prodromal Parkinson's Disease.帕金森病前驱期的概念。
J Parkinsons Dis. 2015;5(4):681-97. doi: 10.3233/JPD-150685.
7
Update on Molecular Imaging in Parkinson's Disease.帕金森病的分子影像学进展。
Neurosci Bull. 2018 Apr;34(2):330-340. doi: 10.1007/s12264-017-0202-6. Epub 2017 Dec 27.
8
Combining Biomarkers with Genetics In Prodromal/Earliest Phase Parkinson's Disease.将生物标志物与遗传学相结合用于前驱期/极早期帕金森病。
J Parkinsons Dis. 2024;14(s2):S345-S351. doi: 10.3233/JPD-240155.
9
Prodromal PD: A new nosological entity.前驱期帕金森病:一种新的分类实体。
Prog Brain Res. 2020;252:331-356. doi: 10.1016/bs.pbr.2020.01.003. Epub 2020 Feb 10.
10
Imaging in Parkinson's Disease.帕金森病的影像学
Int Rev Neurobiol. 2017;132:233-274. doi: 10.1016/bs.irn.2017.02.015. Epub 2017 Mar 30.

引用本文的文献

1
Potential cerebrospinal fluid metabolomic biomarkers and early prediction model for Parkinson's disease.帕金森病潜在的脑脊液代谢组学生物标志物及早期预测模型
Front Aging Neurosci. 2025 May 30;17:1582362. doi: 10.3389/fnagi.2025.1582362. eCollection 2025.
2
Early Changes in the Locus Coeruleus in Mild Cognitive Impairment with Lewy Bodies.路易体轻度认知障碍中蓝斑核的早期变化。
Mov Disord. 2025 Feb;40(2):276-284. doi: 10.1002/mds.30058. Epub 2024 Nov 13.
3
Introduction: The Earliest Phase of Parkinson's Disease: Possibilities for Detection and Intervention.

本文引用的文献

1
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria.帕金森病的生物学分类:SynNeurGe 研究诊断标准。
Lancet Neurol. 2024 Feb;23(2):191-204. doi: 10.1016/S1474-4422(23)00404-0.
2
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义:建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
3
Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review.
引言:帕金森病的最早阶段:检测与干预的可能性
J Parkinsons Dis. 2024;14(s2):S253-S255. doi: 10.3233/JPD-249011.
帕金森病的心脏123I-间碘苄胍(MIBG)闪烁扫描术:一项综述
Brain Sci. 2023 Oct 18;13(10):1471. doi: 10.3390/brainsci13101471.
4
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.α-突触核蛋白 PET 示踪剂[18F]ACI-12589 可将多系统萎缩与其他神经退行性疾病区分开来。
Nat Commun. 2023 Oct 27;14(1):6750. doi: 10.1038/s41467-023-42305-3.
5
Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder.孤立性快速眼动睡眠行为障碍患者脑胆碱能功能障碍的进展。
Eur J Neurol. 2024 Jan;31(1):e16101. doi: 10.1111/ene.16101. Epub 2023 Oct 17.
6
Using F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease.使用 F-AV-133 VMAT2 PET 成像监测帕金森病中的进行性黑质纹状体变性。
Neurology. 2023 Nov 27;101(22):e2314-e2324. doi: 10.1212/WNL.0000000000207748.
7
Subregional analysis of striatum iron in Parkinson's disease and rapid eye movement sleep behaviour disorder.纹状体铁在帕金森病和快速眼动睡眠行为障碍中的亚区分析。
Neuroimage Clin. 2023;40:103519. doi: 10.1016/j.nicl.2023.103519. Epub 2023 Sep 28.
8
Noradrenergic alterations in Parkinson's disease: a combined 11C-yohimbine PET/neuromelanin MRI study.帕金森病中的去甲肾上腺素改变:11C-育亨宾 PET/神经黑色素 MRI 联合研究。
Brain. 2024 Apr 4;147(4):1377-1388. doi: 10.1093/brain/awad338.
9
Cholinergic innervation topography in GBA-associated de novo Parkinson's disease patients.GBA 相关散发性帕金森病患者的胆碱能神经支配分布。
Brain. 2024 Mar 1;147(3):900-910. doi: 10.1093/brain/awad323.
10
Nuclear Imaging Data-Driven Classification of Parkinson's Disease.核医学成像数据驱动的帕金森病分类。
Mov Disord. 2023 Nov;38(11):2053-2063. doi: 10.1002/mds.29582. Epub 2023 Aug 28.